AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20434110 — intervention group
Group type: COMPARATOR
Intervention: 5 mg succinylcholine
Number of subjects: 79
Study 20434110 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 79
Study 18390559 — intervention group
Group type: EXPERIMENTAL
Intervention: Double ejaculate
Number of subjects: 89
Study 18390559 — intervention group
Group type: COMPARATOR
Intervention: Single ejaculate
Number of subjects: 89
Study 16048928 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (3.375 g every 6 h)
Number of subjects: 244
Study 16048928 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem (1 g once a day)
Number of subjects: 244
Study 12090814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 45
Study 10321113 — intervention group
Group type: COMPARATOR
Intervention: Functional MR imaging in healthy volunteers
Number of subjects: 28
Study 10321113 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MR imaging in patients with brain tumours
Number of subjects: 28
Study 10321113 — intervention group
Group type: COMPARATOR
Intervention: Functional MR imaging during left hand motion in healthy volunteers
Number of subjects: 28
Study 10321113 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MR imaging during motion of the affected hand in patients
Number of subjects: 28
Study 8708718 — intervention group
Group type: COMPARATOR
Intervention: FUra/LV alone
Number of subjects: 260
Study 8708718 — intervention group
Group type: EXPERIMENTAL
Intervention: FUra/LV/IFN alpha
Number of subjects: 260
Study 1931703 — intervention group
Group type: EXPERIMENTAL
Intervention: MP/IFN (melphalan/prednisone plus natural IFN alpha)
Number of subjects: 220
Study 1931703 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan/prednisone)
Number of subjects: 220
Study 1931703 — intervention group
Group type: EXPERIMENTAL
Intervention: MP/IFN
Number of subjects: 220
Study 1931703 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 220
Study 6338682 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure (100 dBA for 10 min)
Number of subjects: 13
Study 6338682 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsynaptic alpha‐adrenoceptor blockade (prazosin, 2 mg orally)
Number of subjects: 13
Study 6338682 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined postsynaptic alpha‐ and non‐selective beta‐adrenoceptor blockade (labetalol, 200 mg orally)
Number of subjects: 13
Study 6338682 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 13
Study 29268598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg)
Number of subjects: 90
Study 29268598 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg)
Number of subjects: 90
Study 29268598 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (15 mL)
Number of subjects: 90
Study 31471378 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14
Number of subjects: 466
Study 31471378 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 466
Study 31471378 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 466
Study 31471378 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count
Number of subjects: 466
Study 30041771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) added to conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Number of subjects: 0
Study 30041771 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Number of subjects: 0
Study 27282117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM) initiated in jail
Number of subjects: 300
Study 27282117 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim Methadone (IM) and patient navigation
Number of subjects: 300
Study 27282117 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual
Number of subjects: 300
Study 23760038 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive TKA (mini-midvastus approach)
Number of subjects: 66
Study 23760038 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (medial parapatellar approach)
Number of subjects: 66
Study 23760038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Minimally invasive TKA and Conventional TKA)
Number of subjects: 66
Study 22350859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with didactic textual forms
Number of subjects: 1059
Study 22350859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with graphic imagery of diseased organs
Number of subjects: 1059
Study 22350859 — intervention group
Group type: COMPARATOR
Intervention: Pictorial health warning labels (HWLs) with testimonial narratives
Number of subjects: 1059
Study 22350859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) with didactic forms
Number of subjects: 1059
Study 20799901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature arm (viewing nature scenes and listening to nature sounds)
Number of subjects: 120
Study 20799901 — intervention group
Group type: EXPERIMENTAL
Intervention: City arm (viewing city scenes and listening to city sounds)
Number of subjects: 120
Study 20799901 — intervention group
Group type: COMPARATOR
Intervention: Standard Care arm
Number of subjects: 120
Study 17080429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (creatine monohydrate, coenzyme Q(10), and lipoic acid)
Number of subjects: 16
Study 15604946 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated 3-D quantification method
Number of subjects: 101
Study 15604946 — intervention group
Group type: COMPARATOR
Intervention: Manual quantification method
Number of subjects: 101
Study 12572768 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 0
Study 9458917 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (transdermal patch, approximately 0.1 mg/day)
Number of subjects: 6
Study 9458917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (3% NaCl)
Number of subjects: 6
Study 9458917 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study 9156817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran‐40 based preservation solution (Dex‐PS)
Number of subjects: 174
Study 9156817 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 174
Study 2576685 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 75
Study 2576685 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 75
Study 2576685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 75
Study 2576685 — intervention group
Group type: COMPARATOR
Intervention: d‐tubocurarine
Number of subjects: 75
Study 2576685 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 75
Study 937570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) with transitional day care available
Number of subjects: 175
Study 937570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) without day care
Number of subjects: 175
Study 937570 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient care (discharge at the therapist's discretion)
Number of subjects: 175
Study 30601581 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 112
Study 30601581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 28601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial density (MD) in healthy eyes
Number of subjects: 60
Study 28601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-prosthesis MD
Number of subjects: 60
Study 28601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Gram-negative bacteria in retro-prosthesis samples
Number of subjects: 60
Study 28601909 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (excluding S. epidermidis) in retro-prosthesis samples
Number of subjects: 60
Study 23768947 — intervention group
Group type: EXPERIMENTAL
Intervention: Existential Behavioural Therapy (EBT) with mindfulness training
Number of subjects: 130
Study 23521205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 22
Study 23521205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 22
Study 23521205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21806579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing cervical canal using sterile cotton swabs prior to embryo transfer
Number of subjects: 530
Study 21806579 — intervention group
Group type: COMPARATOR
Intervention: Routine embryo transfer
Number of subjects: 530
Study 20121952 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised endurance exercise training (ET) program, walking and stationary cycling, three times per week for 30 to 40 minutes at moderate intensity
Number of subjects: 59
Study 20121952 — intervention group
Group type: COMPARATOR
Intervention: Attention-control, nonexercise, usual care control group
Number of subjects: 59
Study 20121952 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week supervised endurance exercise training (ET) program
Number of subjects: 59
Study 16452132 — intervention group
Group type: EXPERIMENTAL
Intervention: New protocol for inter-physician information exchange
Number of subjects: 91
Study 16452132 — intervention group
Group type: COMPARATOR
Intervention: Standard Belgian evaluation protocol
Number of subjects: 91
Study 15605960 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning about the imagination inflation effect
Number of subjects: 0
Study 15605960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warning)
Number of subjects: 0
Study 11242723 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine 20% oral adhesive (Orabase-B)
Number of subjects: 40
Study 11242723 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine 20% gel (Hurricaine)
Number of subjects: 40
Study 11242723 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% oral adhesive (EMLA 5% cream in Orabase Plain)
Number of subjects: 40
Study 9140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 0
Study 9140802 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg once daily
Number of subjects: 0
Study 9140802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8274289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M sphingosine in ethanol
Number of subjects: 35
Study 8274289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 M sphingosine in ethanol
Number of subjects: 35
Study 8274289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0/0.2% isoquinoline in white vaseline/lanette wax cream
Number of subjects: 35
Study 8274289 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/10% tannic acid in lanette wax cream
Number of subjects: 35
Study 8274289 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% coal tar
Number of subjects: 35
Study 8274289 — intervention group
Group type: COMPARATOR
Intervention: 0.0/0.1/0.2 M sphingosine in ethanol
Number of subjects: 35
Study 2884735 — intervention group
Group type: EXPERIMENTAL
Intervention: salazopyridazin
Number of subjects: 0
Study 2884735 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazin
Number of subjects: 0
Study 2884735 — intervention group
Group type: COMPARATOR
Intervention: d-Penicillamin
Number of subjects: 0
Study 31907662 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 48
Study 31907662 — intervention group
Group type: COMPARATOR
Intervention: Carbon nanoparticles (CN)
Number of subjects: 48
Study 29176391 — intervention group
Group type: EXPERIMENTAL
Intervention: Average on-treatment SBP less than 142 mmHg (lowest tertile)
Number of subjects: 7998
Study 29176391 — intervention group
Group type: EXPERIMENTAL
Intervention: Average SBP of 142 mmHg to less than 152 mmHg (middle tertile)
Number of subjects: 7998
Study 29176391 — intervention group
Group type: COMPARATOR
Intervention: Average SBP of at least 152 mmHg (highest tertile and reference group)
Number of subjects: 7998
Study 27214300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg
Number of subjects: 115
Study 27214300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 25959747 — intervention group
Group type: EXPERIMENTAL
Intervention: All routine vaccinations at birth (BCG/OPV/HBV)
Number of subjects: 120
Study 25959747 — intervention group
Group type: COMPARATOR
Intervention: BCG delayed until after the study period (at day 5)
Number of subjects: 120
Study 25959747 — intervention group
Group type: COMPARATOR
Intervention: All routine vaccinations delayed until after the study period
Number of subjects: 120
Study 23478997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low literacy
Number of subjects: 595
Study 20500867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory second look surgery with CRS and HIPEC (intraperitoneal oxaliplatin with concurrent systemic 5-fluorouracil and leucovorin)
Number of subjects: 100
Study 20500867 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (routine surveillance)
Number of subjects: 100
Study 18629590 — intervention group
Group type: EXPERIMENTAL
Intervention: High SES in low-deductible plans
Number of subjects: 528
Study 18629590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES in high-deductible plans
Number of subjects: 528
Study 18629590 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy recommendation for high SES in low-deductible plans
Number of subjects: 528
Study 18629590 — intervention group
Group type: COMPARATOR
Intervention: Inappropriate screening recommendations
Number of subjects: 528
Study 16817817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (1 mg 17beta oestradiol and 0.5 mg norethisterone acetate)
Number of subjects: 50
Study 16817817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12821734 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftriaxone for 28 days
Number of subjects: 55
Study 12821734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10819315 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate, 1,000 microg/d for 8 weeks
Number of subjects: 19
Study 10819315 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 19
Study 8774024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapping with the forefinger of the nonpreferred hand throughout the task
Number of subjects: 66
Study 8774024 — intervention group
Group type: COMPARATOR
Intervention: No tapping (control group)
Number of subjects: 66
Study 1628373 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 125 mg MPN
Number of subjects: 20
Study 1628373 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 125 mg MPN
Number of subjects: 20
Study 6432200 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl, twice daily infusions
Number of subjects: 32
Study 6432200 — intervention group
Group type: COMPARATOR
Intervention: 4% dextrose and saline infusion (control)
Number of subjects: 32
Study 31122211 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil (PR)
Number of subjects: 80
Study 31122211 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil (DR)
Number of subjects: 80
Study 29182791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg/day for 7 days plus standardized topical treatment (moderately strong steroid and moisturizer)
Number of subjects: 39
Study 29182791 — intervention group
Group type: COMPARATOR
Intervention: Standardized topical treatment alone (control group)
Number of subjects: 39
Study 27067305 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief quitline facilitation intervention (5-minute intervention with warm handoff or faxed referral to a national quitline provider)
Number of subjects: 600
Study 27067305 — intervention group
Group type: COMPARATOR
Intervention: Brief cessation advice (control group)
Number of subjects: 600
Study 24762381 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous oxygen peroxide (AOP) treatment
Number of subjects: 61
Study 24762381 — intervention group
Group type: COMPARATOR
Intervention: Sterile water placebo
Number of subjects: 61
Study 22352336 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Number of subjects: 65
Study 22352336 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) 300/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Number of subjects: 65
Study 22352336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DRV/r and ATV/r
Number of subjects: 65
Study 19546163 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 17686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (Ca)
Number of subjects: 10
Study 17686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (F)
Number of subjects: 10
Study 17686453 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pre-rinse (Ca) with fluoride dentifrice (F)
Number of subjects: 10
Study 16129089 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based component of a nutrition and physical activity behavioral intervention
Number of subjects: 194
Study 12392804 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational psychotherapy
Number of subjects: 279
Study 12392804 — intervention group
Group type: EXPERIMENTAL
Intervention: Series of treatment-related videos
Number of subjects: 279
Study 12392804 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 279
Study 11817338 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine rinse (0.12 mM)
Number of subjects: 43
Study 11817338 — intervention group
Group type: COMPARATOR
Intervention: Control (without adenosine)
Number of subjects: 43
Study 7672157 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d of vitamin E
Number of subjects: 30
Study 7672157 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablets
Number of subjects: 30
Study 2123160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate (n = 21)
Number of subjects: 40
Study 2123160 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buserelin acetate (n = 19)
Number of subjects: 40
Study 2123160 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both routes (IN vs SC)
Number of subjects: 40
Study 2123160 — intervention group
Group type: COMPARATOR
Intervention: Correlation with initial fibroid size
Number of subjects: 40
Study 2123160 — intervention group
Group type: COMPARATOR
Intervention: Correlation with patient age
Number of subjects: 40
Study 464030 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofeedback therapy
Number of subjects: 22
Study 464030 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 31522234 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 475
Study 31522234 — intervention group
Group type: COMPARATOR
Intervention: PSA/DRE strategy
Number of subjects: 475
Study 30629728 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intranasal neurostimulation
Number of subjects: 58
Study 30629728 — intervention group
Group type: COMPARATOR
Intervention: Sham control intranasal stimulation
Number of subjects: 58
Study 30629728 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 58
Study 28153666 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue (Dermabond; Ethicon)
Number of subjects: 104
Study 28153666 — intervention group
Group type: COMPARATOR
Intervention: Monofilament sutures (Monocryl; Ethicon)
Number of subjects: 104
Study 26474867 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention consisting of three workshops aimed at reducing excessive physical workloads.
Number of subjects: 80
Study 26474867 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical measurements (EMG, accelerometers, video recordings) before and after the intervention.
Number of subjects: 80
Study 24148211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 57
Study 24148211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adenotonsillectomy)
Number of subjects: 57
Study 21255134 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (higher doses)
Number of subjects: 518
Study 21255134 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (lower and higher doses)
Number of subjects: 518
Study 21255134 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran
Number of subjects: 518
Study 21255134 — intervention group
Group type: COMPARATOR
Intervention: aspirin alone
Number of subjects: 518
Study 19184083 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncircular chainring system (ROT)
Number of subjects: 15
Study 19184083 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncircular chainring system (ROT+)
Number of subjects: 15
Study 19184083 — intervention group
Group type: COMPARATOR
Intervention: Conventional chainring system (CON)
Number of subjects: 15
Study 17696035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity laser therapy (LILT) with infrared laser (780 nm, 70 mW, 10 s, 89.7 J/cm2), applied twice a week for four weeks.
Number of subjects: 48
Study 17696035 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control) using identical probes, one active and one that does not emit radiation.
Number of subjects: 48
Study 15262483 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 0
Study 11442705 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident Assessment Instrument (RAI)
Number of subjects: 348
Study 11442705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RAI implementation)
Number of subjects: 348
Study 9876394 — intervention group
Group type: EXPERIMENTAL
Intervention: Schuss view
Number of subjects: 32